Cytosorbents Corporation (NASDAQ:CTSO) Sellers Increased By 3% Their Shorts

January 16, 2018 - By Vivian Park

 Cytosorbents Corporation (NASDAQ:CTSO) Sellers Increased By 3% Their Shorts

Investors sentiment increased to 1.27 in 2017 Q3. Its up 0.54, from 0.73 in 2017Q2. It is positive, as 8 investors sold Cytosorbents Corporation shares while 3 reduced holdings. 6 funds opened positions while 8 raised stakes. 2.38 million shares or 26.98% more from 1.87 million shares in 2017Q2 were reported.
Skylands Cap Ltd Limited Liability Company has invested 0.41% in Cytosorbents Corporation (NASDAQ:CTSO). Moreover, Wells Fargo & Mn has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO). Peak6 Invs Lp has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Jpmorgan Chase & Comm invested 0% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO). National Bank & Trust Of Ny Mellon holds 0% or 25,519 shares in its portfolio. Moreover, Group Inc One Trading L P has 0% invested in Cytosorbents Corporation (NASDAQ:CTSO). State Street reported 12,000 shares. California Employees Retirement Sys accumulated 46,100 shares or 0% of the stock. Vanguard Gp has invested 0% in Cytosorbents Corporation (NASDAQ:CTSO). Millennium Management Llc reported 41,217 shares stake. Geode Lc owns 127,125 shares. Manatuck Hill Prtnrs Ltd Liability has 0.45% invested in Cytosorbents Corporation (NASDAQ:CTSO). Fortaleza Asset Mngmt holds 0.27% of its portfolio in Cytosorbents Corporation (NASDAQ:CTSO) for 23,375 shares. Royal Comml Bank Of Canada reported 2,805 shares stake. Morgan Stanley invested in 0% or 6,862 shares.

Since January 8, 2018, it had 0 insider purchases, and 1 insider sale for $236,400 activity.

The stock of Cytosorbents Corporation (NASDAQ:CTSO) registered an increase of 3% in short interest. CTSO’s total short interest was 1.36M shares in January as published by FINRA. Its up 3% from 1.32M shares, reported previously. With 183,900 shares average volume, it will take short sellers 7 days to cover their CTSO’s short positions. The short interest to Cytosorbents Corporation’s float is 6.63%.

It closed at $7.8 lastly. It is down 4.26% since January 16, 2017 and is downtrending. It has underperformed by 20.96% the S&P500.

CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. The company has market cap of $223.79 million. The Company’s principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It currently has negative earnings. The firm also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

Cytosorbents Corporation (NASDAQ:CTSO) Ratings Coverage

Among 7 analysts covering CytoSorbents (NASDAQ:CTSO), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents has $14.0 highest and $7 lowest target. $11.07’s average target is 41.92% above currents $7.8 stock price. CytoSorbents had 13 analyst reports since October 29, 2015 according to SRatingsIntel. On Tuesday, September 26 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 9. Aegis Capital initiated Cytosorbents Corporation (NASDAQ:CTSO) on Wednesday, October 26 with “Buy” rating. The firm earned “Buy” rating on Wednesday, July 5 by Maxim Group. The company was maintained on Tuesday, August 8 by Maxim Group. Maxim Group initiated it with “Buy” rating and $8 target in Tuesday, May 24 report. The firm earned “Buy” rating on Tuesday, May 30 by Aegis Capital. The stock of Cytosorbents Corporation (NASDAQ:CTSO) has “Buy” rating given on Friday, October 7 by B. Riley & Co. The stock of Cytosorbents Corporation (NASDAQ:CTSO) earned “Buy” rating by Maxim Group on Monday, July 17. The stock of Cytosorbents Corporation (NASDAQ:CTSO) earned “Buy” rating by WBB Securities on Thursday, October 29.

More notable recent Cytosorbents Corporation (NASDAQ:CTSO) news were published by: Prnewswire.com which released: “CytoSorbents to Report Q2 2017 Operating and Financial Results” on August 01, 2017, also Seekingalpha.com with their article: “Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position” published on August 04, 2017, Seekingalpha.com published: “CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call …” on August 08, 2017. More interesting news about Cytosorbents Corporation (NASDAQ:CTSO) were released by: Seekingalpha.com and their article: “Cytosorbents: A Razor & Razor Blade Story” published on June 28, 2017 as well as Seekingalpha.com‘s news article titled: “Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results – Earnings Call …” with publication date: November 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.